UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000033924
Receipt No. R000037594
Scientific Title Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS
Date of disclosure of the study information 2018/08/28
Last modified on 2019/04/11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS
Acronym Retrospective chart review on long-term treatment with natalizumab in Japanese patients with RRMS
Scientific Title Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS
Scientific Title:Acronym Retrospective chart review on long-term treatment with natalizumab in Japanese patients with RRMS
Region
Japan

Condition
Condition Relapsing-Remitting Multiple Sclerosis
Classification by specialty
Neurology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To determine the presence or absence of new active lesions in MRI by assessing new or newly-enlarging T2-hyperintense lesions before and after treatment with natalizumab
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The proportion of subjects with new/newly enlarging T2-hyperintense lesions after treatment (each year up to 5 years)
Key secondary outcomes The changes after treatment (each year up to 5 years) in the following:
- Proportion of subjects with new Gd-enhancing lesions
- Clinical relapse rate (ARR)
- Expanded disability status scale
- Anti-JCV antibody index

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Relapsing-Remitting Multiple Sclerosis
2. 18 years old or over
3.Treated for at least 1 year with natalizumab (including patients who discontinued after receiving natalizumab for more than 1 year).
4. No treatment gap of more than 12 weeks
Key exclusion criteria Refusal of consent by opt-out prior to the initiation of the study
Target sample size 80

Research contact person
Name of lead principal investigator
1st name Takahiko
Middle name
Last name Saida
Organization IRINO MEDICAL CLINIC, LLC
Division name Neurology
Zip code 556-0016
Address 2-3-19 Motomachi, Naniwa-ku, Osaka, Japan
TEL 090-2287-1021
Email saida_takahiko@icloud.com

Public contact
Name of contact person
1st name Takahiko
Middle name
Last name Saida
Organization IRINO MEDICAL CLINIC, LLC
Division name Neurology
Zip code 556-0016
Address 2-3-19 Motomachi, Naniwa-ku, Osaka, Japan
TEL 090-2287-1021
Homepage URL
Email saida_takahiko@icloud.com

Sponsor
Institute IRINO MEDICAL CLINIC, LLC
Institute
Department

Funding Source
Organization Biogen Japan Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Medical corporation Tokeikai Kitamachi clinic ethics review committee
Address 1-1-3 Kichijoji Kitamachi, Musashino City, Tokyo
Tel 03-6779-8166
Email shingo-namiki@j-smo.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人入野医院(大阪府)

Other administrative information
Date of disclosure of the study information
2018 Year 08 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 85
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2018 Year 03 Month 26 Day
Date of IRB
2018 Year 03 Month 26 Day
Anticipated trial start date
2018 Year 08 Month 28 Day
Last follow-up date
2019 Year 03 Month 30 Day
Date of closure to data entry
2019 Year 04 Month 02 Day
Date trial data considered complete
2019 Year 04 Month 05 Day
Date analysis concluded
2019 Year 05 Month 31 Day

Other
Other related information Retrospective study using existing medical records ( 1 February, 2010 - 31 January, 2018 ) in participating medical institution.

Management information
Registered date
2018 Year 08 Month 28 Day
Last modified on
2019 Year 04 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037594

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.